

**ATTENTION- DEFICIT HYPERACTIVITY DISORDER (ADHD)
QUANTITY LIMITATION
UTILIZATION MANAGEMENT CRITERIA**

DRUG CLASS: Stimulants and Non-Stimulants

BRAND (generic) NAMES: Adderall® (amphetamine/dextroamphetamine)
 Adderall XR® (amphetamine/ dextroamphetamine ER)
 Adzenys XR-ODT™ (amphetamine ER dispersible)
 Aptensio XR® (methylphenidate ER)
 Concerta® (methylphenidate ER)
 Daytrana® (methylphenidate transdermal patch)
 Dextroamphetamine (DextroStat®)
 Dexedrine® (dextroamphetamine ER)
 Dyanavel™ XR (amphetamine ER)
 Focalin XR® (dexmethylphenidate ER)
 Focalin® (dexmethylphenidate)
 Intuniv® (guanfacine ER)
 Kapvay® (clonidine ER)
 Metadate CD® (methylphenidate ER)
 Metadate ER® (methylphenidate ER)
 Methylin® (methylphenidate)
 Procentra® (dextroamphetamine)
 Quillichew™ (methylphenidate ER)
 Quillivant XR® (methylphenidate ER)
 Ritalin® (methylphenidate)
 Ritalin® LA (methylphenidate ER)
 Ritalin® SR (methylphenidate ER)
 Strattera® (atomoxetine)
 Vyvanse® (lisdexamphetamine)
 Zenzedi® (dextroamphetamine)

COVERAGE AUTHORIZATION CRITERIA

Non-formulary medications - Medications included in this criterion that are not part of **ASO Net Results or Essential Formularies** are subject to a trial and failure of up to **TWO** formulary alternatives that are clinically appropriate, to treat the same condition, prior to approval (see Non-formulary Exception Criteria for detailed limitations).

Quantities above the program set limit (see pgs 2-4) for **ADHD agents** will be approved when the following is met:

1. The quantity (dose) requested is for documented titration purposes at the initiation of therapy (authorization for a 90 day titration period); **AND**
2. The prescribed dose cannot be achieved using a lesser quantity of a higher strength; **AND**
3. The quantity (dose) requested does not exceed the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer's product insert; **OR**

4. If the quantity (dose) requested exceeds the maximum FDA labeled dose, when specified, or to the safest studied dose per the manufacturer's product insert, then the prescriber must submit documentation in support of therapy with a higher dose for the intended diagnosis (submitted documentation may include medical records OR fax form which reflects medical record documentation that shows the length of time the requested dose has been used, and what other medications and doses have been tried and failed); **AND**
5. For members whose products are marked as Restricted Access on the Basic Open and Essential Formularies have additional requirements of;
 - a) FDA approved indication; **AND**
 - b) A trial and failure of **TWO** unrestricted medications; **OR**
 - c) A clinical contraindication/intolerance to those medication not been tried. Referenced policy found:
www.bcbsnc.com/assets/services/public/pdfs/formulary/Restricted_Access_ESBO.pdf

Durration of Approval: 365 days

QUANTITY LIMITS

Medication Name/Strength	Quantity Limit per Day	Recommended Dosing per FDA Label	Max Daily Dose/Maximum Dose Studied per FDA Label
Adderall (amphetamine/ dextroamphetamine)			
5mg	3 tablets	ADHD: 40mg/day Narcolepsy: 60mg/day in divided doses	ADHD (Pediatric and Adults): Not to exceed 40mg/day except only in rare cases Narcolepsy: 60mg/day in divided doses
7.5mg			
10mg			
12.5mg			
15mg			
20mg			
30mg	2 tablets		
Adderall XR (amphetamine/ dextroamphetamine extended release)			
5mg	1 capsule	Pediatric (6-17 yoa): 30mg daily Adults: 20mg QAM	Pediatric (6-17 yoa): 10mg to 40mg per day studied; no adequate evidence that doses greater than 20mg/day conferred additional benefit Adults: 20mg to 60mg per day studied; no adequate evidence that doses greater than 20mg/day conferred additional benefit
10mg			
15mg			
20mg			
25mg			
30mg			
Adzenys XR-ODT (amphetamine ER dispersible)			
3.1mg	1 tablet	Pediatric (6-12 yoa) : 6.3 mg to 18.8 mg once daily Pediatric (13-17 yoa) : 6.3 mg to 12.5 mg once daily Adults: 12.5 mg once daily	Pediatric (6-12 yoa): 18.8 mg once daily Pediatric (13-17 yoa) : 12.5 mg once daily Adults: 18.8 mg once daily
6.3mg			
9.4 mg			
12.5mg			
15.7mg			
18.8mg			
Aptensio XR (methylphenidate extended release)			
10mg	1 capsule	ADHD (≥6 yoa): 10-60mg/day; one capsule in the AM	ADHD (Pediatric and Adults): Doses greater than 60mg per day have not been studied and are not recommended
15mg			
20mg			
30mg			
40mg			
50mg			
60mg	Concerta (methylphenidate extended release)		

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. BCBSNC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

18mg	1 tablet	Pediatric (6-12yoa): 18mg to 54mg once daily	Pediatric (6-12yoa): Doses greater than 54mg per day have not been studied and are not recommended
27mg			
36mg	2 tablets	Pediatric (13-17yoa): 18mg to 72mg once daily Adults (18-65yoa): 18mg to 72mg once daily	Pediatric (13-17yoa): Doses greater than 72mg per day have not been studied and are not recommended Adults (18-65yoa): Doses greater than 72mg per day have not been studied and are not recommended
54mg	1 tablet		
Daytrana (methylphenidate transdermal patch)			
10mg/9hr	1 patch	10mg to 30mg/9hr patch	Doses greater than 30mg/9hr were not studied
15mg/9hr			
20mg/9hr			
30mg/9hr			
Dextroamphetamine (DextroStat)			
5mg	2 tablets	Narcolepsy: 5-60mg/day in divided doses ADHD: 40mg/day	ADHD: Per FDA label, only in rare cases will it be necessary to exceed a total of 40 mg per day.
10mg	6 tablets		
Dexedrine (dextroamphetamine extended release)			
5mg	3 capsules	Narcolepsy: 5-60mg/day in divided doses. ADHD: 40mg/day	ADHD: Per FDA label, only in rare cases will it be necessary to exceed a total of 40 mg per day.
10mg	4 capsules		
15mg	4 capsules		
Dyanavel XR (amphetamine extended release)			
2.5mg per 1mL	8 mL	ADHD: In children 6 years of age and older, recommended starting dose is 2.5 mg or 5 mg once daily in the morning. Dosage may be increased in increments of 2.5 mg to 10 mg per day every 4 to 7 days until optimal response is obtained.	ADHD: Per FDA label, daily doses above 20mg are not recommended.
Focalin XR (dexmethylphenidate extended release)			
5mg	1 capsule	Recommended for once daily dosing. Adults: Up to 40mg/day Children(6-17yoa): Up to 30mg/day	Per FDA label, doses above 30mg/day in pediatrics and 40mg/day in adults have not been studied and are not recommended.
10mg			
15mg			
20mg			
25mg			
30mg			
35mg			
40mg			
Focalin (dexmethylphenidate)			
2.5mg	3 tablets	Administered twice daily at least 4 hours apart. Adults: 20mg/day Children (6-17yoa): 20mg/day	Per FDA label, the maximum recommended dose is 20mg/day (10mg twice daily).
5mg	3 tablets		
10mg	2 tablets		
Intuniv (guanfacine extended release)			
1mg	1 tablet	1-4mg once daily in the AM or PM	Per the FDA label, doses above 4mg/day have not been systematically studied in controlled clinical studies.
2mg			
3mg			
4mg			
Kapvay (clonidine extended release)			

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. BCBSNC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

0.1mg	4 tablets	0.2mg given twice daily	Per FDA label, doses greater than 0.4mg/day were not evaluated in clinical trials for ADHD and are not recommended.
0.2mg	Only available in starter pack		
Metadate CD (methylphenidate extended release)			
10mg	1 capsule	Administered once daily in the morning. Up to 60mg/day.	Per FDA label, daily dosage above 60mg is not recommended.
20mg			
30mg			
40mg			
50mg			
60mg			
Metadate ER (methylphenidate extended release)			
10mg	3 tablets	Up to 60mg/day	Children ≥6yo: Per FDA label, daily dosage above 60mg/day is not recommended.
20mg			
Methylin Chew Tabs and Solution (methylphenidate)			
2.5mg	3 chewable tablets	20 to 30mg/day in 2 or 3 divided doses. Can titrate to 40 to 60mg/day	Children ≥6yo: Per FDA label, daily dosage above 60mg/day is not recommended.
5mg	3 chewable tablets		
10mg	6 chewable tablets		
5mg/5mL	15mL		
10mg/5mL	30mL		
Procentra (dextroamphetamine)			
5mg/5mL	60mL	Narcolepsy: Up to 60mg/day in divided doses ADHD: Up to 40mg/day	ADHD: Per FDA label, only in rare cases will it be necessary to exceed a total of 40mg/day.
Quilichew ER (methylphenidate extended release)			
20mg	1 tablet	ADHD: For patients 6 years and above, recommended starting dose is 20 mg given orally once daily in the morning; may be increased weekly in increments of 10 mg to 20 mg per day.	Per the FDA label, daily dosage above 60 mg is not recommended.
30mg	2 tablets		
40mg	1 tablet		
Quillivant XR (methylphenidate extended release)			
25 mg/5 mL	60mg or 12mL	ADHD: For patients 6 years and above, recommended starting dose is 20 mg given orally once daily in the morning; may be increased weekly in increments of 10 mg to 20 mg per day. Daily dosage above 60 mg is not recommended.	ADHD: Per FDA label, dosage >60mg/day is not recommended. Doses up to 60mg/day were studied in clinical trials.
Ritalin (methylphenidate)			
5mg	3 tablets	20 to 30mg/day in 2 or 3 divided doses. Can titrate to 40 to 60mg/day	Children ≥6yo: Per FDA label, daily doses above 60mg/day is not recommended.
10mg			
20mg			
Ritalin LA (methylphenidate extended release)			
10mg	1 capsule	The recommended starting dose is 20mg once daily. Daily dosage above 60mg is not recommended.	Per FDA label: daily dosage above 60mg is not recommended.
20mg	1 capsule		
30mg	2 capsules		
40mg	1 capsule		
60mg	1 capsule		
Ritalin SR (methylphenidate extended release)			
20mg	3 tablets	60mg/day	Children ≥6yo: Per FDA label, daily doses above 60mg/day is not recommended.
Strattera (atomoxetine)			
10mg	2 capsules	Children and adolescents up to 70kg: target daily dose 1.2mg/kg and a max daily dose of 1.4mg/kg	Children and adolescents: Doses of 0.5 to 1.8mg/kg/day were studied; 1.8mg/kg/day dose did not provide any additional benefit over that observed with the 1.2mg/kg/day dose.
18mg			
25mg			
40mg			
60mg			
80mg	1 capsule		

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. BCBSNC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

100mg		Children and adolescents over 70kg and adults: target daily dose 80mg with a max daily dose of 100mg Dose adj: Hepatic impairment, CYP2D6 inhibitor.	Adults: Doses of 60 to 120mg/day were studied; mean final dose was approximately 95mg/day.
Vyvanse (lisdexamphetamine)			
10mg	1 capsule	Recommended starting dose is 30mg QD; maximum daily dose of 70mg QD	Per the FDA label, doses >70mg/day were not studied in clinical trials. Only once daily doses were studied.
20mg			
30mg			
40mg			
50mg			
60mg			
70mg			
Zenedi (dextroamphetamine)			
2.5mg	3 tablets	Narcolepsy: Up to 60mg/day ADHD: Up to 40mg/day	ADHD: Per FDA label, only in rare cases will it be necessary to exceed a total of 40mg/day.
5mg	2 tablets		
7.5mg	8 tablets		
10mg	6 tablets		
15mg	2 tablets		
20mg	3 tablets		
30mg	2 tablets		

POLICY IMPLEMENTATION/UPDATE INFORMATION

February 2017: referenced policy for Basic Open and Essential formulary Restricted Access policy; added provision for titration in quantity limit exception criteria.

January 2017: Zedzeni 2.5 QL adjusted to 3 as it was erroneously marked as 6.

January 2017: Reviewed for ASO Net Results and Essential Formularies; Non-formulary verbiage added.

March 2016: Added new to market drug, Adzenys XR-ODT

February 2016: Added new to market medications, Dynavel XR and Quillicher ER to the policy.

August 2015: Revision - Evekeo and Desoxyn removed from the ADHD QL criteria and added to their own program with ADHD QL and Short Term Weight Loss PA

Non-Discrimination and Accessibility Notice

Discrimination is Against the Law

- Blue Cross and Blue Shield of North Carolina (“BCBSNC”) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex.
- BCBSNC does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. BCBSNC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the property of their respective owners.

BCBSNC:

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
 - Qualified interpreters
 - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
 - Qualified interpreters
 - Information written in other languages
- If you need these services, contact Customer Service **1-888-206-4697**, TTY and TDD, call **1-800-442-7028**.
- If you believe that BCBSNC has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with:
 - BCBSNC, PO Box 2291, Durham, NC 27702, Attention: Civil Rights Coordinator- Privacy, Ethics & Corporate Policy Office, Telephone **919-765-1663**, Fax **919-287-5613**, TTY **1-888-291-1783**
civilrightscordinator@bcbsnc.com
- You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, Civil Rights Coordinator - Privacy, Ethics & Corporate Policy Office is available to help you.
- You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at: U.S. Department of Health and Human Services 200 Independence Avenue, SW Room 509F, HHH Building Washington, D.C. 20201 **1-800-368-1019, 800-537-7697** (TDD). Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.
- This Notice and/or attachments may have important information about your application or coverage through BCBSNC. Look for key dates. You may need to take action by certain deadlines to keep your health coverage or help with costs. You have the right to get this information and help in your language at no cost. Call Customer Service **1-888-206-4697**.

ATTENTION: If you speak another language, language assistance services, free of charge, are available to you. Call 1-888-206-4697 (TTY: 1-800-442-7028).

ATENCIÓN: Si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1-888-206-4697 (TTY: 1-800-442-7028).

注意：如果您講廣東話或普通話，您可以免費獲得語言援助服務。請致電 1-888-206-4697

(TTY : 1-800-442-7028)。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn.

Gọi số

1-888-206-4697 (TTY: 1-800-442-7028).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다.

1-888-206-4697 (TTY: 1- 800-442-7028)번으로 전화해 주십시오.

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-888-206-4697 (ATS : 1-800-442-7028).

ملحوظة: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 1-888-206-4697. المبرقة الكاتبة: 1-800-442-7028.

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau

1-888-206-4697 (TTY: 1-800-442-7028).

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1-888-206-4697 (телетайп: 1-800-442-7028).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 1-888-206-4697 (TTY: 1-800-442-7028).

સુચના: જો તમે ગુજરાતી બોલતા હો, તો નિ:સુલ્ક ભાષા સહાય સેવાઓ તમારા માટે ઉપલબ્ધ છે. ફોન કરો

1-888-206-4697 (TTY: 1-800-442-7028).

ចំណាំ: ប្រសិនបើលោកអ្នកនិយាយជាភាសាខ្មែរ សេវាកម្មជំនួយផ្នែកភាសាមានផ្តល់ជូនសម្រាប់លោកអ្នកដោយមិនគិតថ្លៃ។ សូមទំនាក់ទំនងតាមរយៈលេខ: 1-888-206-4697 (TTY: 1-800-442-7028)។

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1-888-206-4697 (TTY: 1-800-442-7028).

ध्यान दें: यदि आप हिन्दी बोलते हैं तो आपके लिए मुफ्त में भाषा सहायता सेवाएं उपलब्ध हैं। 1-888-206-4697 (TTY: 1-800-442-7028) पर कॉल करें।

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1-888-206-4697 (TTY: 1-800-442-7028).

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。1-888-206-4697（TTY: 1-800-442-7028）まで、お電話にてご連絡ください。